Pharma teams spend years building Paragraph IV strategiesmodels, counsel, timelines, war rooms. But the real game often isnt Can we file first? Its Can we anticipate how the brand will move before you even see the move?
Thats the uncomfortable truth be…
Predictable by Design: How Brands Outmaneuver Your Paragraph IV Strategy Read Post »
Drug patent disputes arent won by vibestheyre won by math.
If youre treating a patent settlement as your default strategy in life sciences, you may be paying for a belief system, not for a plan.
Heres the uncomfortable truth: settlements feel like pr…
Takeda v. Sun Pharma isnt just another patent caseits a referendum on how courts will treat modern drug inventorship.
Patent litigation in pharma rarely stays confined to the courtroom. It ripples through R&D calendars, investor expectations, and t…
TAKEDA PHARMACEUTICALS U.S.A., INC. v. SUN PHARMACEUTICAL INDUSTRIES LTD. Read Post »
Short answer: Yesmost clinicians recommend checking liver‑function tests (LFTs) before starting simvastatin (Lipitor)… https://www.Drugchatter.com/chat/30440/is-liver-function-monitoring-necessary-with-lipitor/
DrugChatter: Is liver function monitoring necessary with lipitor? Read Post »
What flexibility side effect are you referring to with Lipitor? Lipitor (atorvastatin) is known for specific… https://www.Drugchatter.com/chat/25856/can-lipitor’s-flexibility-side-effect-lead-to-long-term-issues/
DrugChatter: Can lipitor’s flexibility side effect lead to long term issues? Read Post »
Pharma IP teams didnt wake up one morning and decide to move tools. They decided they couldnt afford to keep making decisions in the dark.
Thats the subtext behind a question going around boardrooms and patent departments right now: why are pharma IP l…
Patent Analyst Suite vs Market Research: Why Pharma IP Teams Are Switching Read Post »
The Bio-better strategy is quietly reshaping the $150B biologics marketand its turning biosimilar momentum into a slower, more expensive fight.
If youve been tracking biosimilars, you may have noticed the headlines: approvals are up, uptake is improvin…
Stop copying molecules. Start competing on delivery.
For years, pharmas me-too instinct has been simple: find the closest known small molecule, file around the relevant claims, and let time and litigation do the rest. But the next wave of competitive a…
Stop Copying Molecules: Patent Drug Delivery Systems Instead Read Post »
Pharma IP strategy is often framed as a binary: win fast or wait out the clock. But Hatch-Waxman and the BPCIA have taught the market something more ruthless: timing is destinydown to the calendar day.
Thats why the 5-year vs. 12-year exclusivity debat…
Branded-generic launches are where pricing bets get madeand where many teams still fly blind.
The window between first notice and market reality is short. Competitors move fast, payers respond quickly, and channel partners dont wait for your internal d…